<DOC>
	<DOCNO>NCT01525407</DOCNO>
	<brief_summary>This phase II trial study donor atorvastatin treatment prevention severe acute graft-versus-host disease ( GVHD ) patient undergo myeloablative peripheral blood stem cell ( PBSC ) transplantation . Giving chemotherapy total-body irradiation ( TBI ) donor PBSC transplant help stop growth cancer cell . It may also prevent patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving atorvastatin donor transplant may prevent happen .</brief_summary>
	<brief_title>Donor Atorvastatin Treatment Preventing Severe Acute Graft-Versus-Host Disease Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess whether 2 week donor statin treatment reduces risk severe acute GVHD . SECONDARY OBJECTIVES : I . To assess whether 2 week statin treatment normal PBSC donor feasible , tolerable safe . OUTLINE : Donors receive atorvastatin orally ( PO ) begin day -14 continue last day stem cell collection .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Human leukocyte antigen ( HLA ) identical sibling donor Myeloablative preparative regimen ( i.e. , &gt; = TBI 12.0 Gy , &gt; = busulfan ( BU ) 8.0 mg/kg PO , &gt; = BU 6.4 mg/kg intravenously ( IV ) , &gt; = treosulfan 42 g/m^2 IV ) accord investigational study standard treatment plan ; `` myeloablative '' preparative regimen acceptable long approve principal investigator designee Transplantation PBSC Cyclosporine ( CSP ) base postgrafting immunosuppression Willingness give inform consent DONOR : Age &gt; = 18 year DONOR : HLA genotypically identical sibling DONOR : Willingness give informed consent Nonmyeloablative preparative regimen Participation investigational study acute GVHD primary endpoint The allogeneic PBSC donor contraindication statin treatment DONOR : Age &lt; 18 year DONOR : Active liver disease ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] level &gt; 2 time upper limit normal [ ULN ] ) DONOR : History myopathy DONOR : Hypersensitivity atorvastatin DONOR : Pregnancy DONOR : Nursing mother DONOR : Current serious systemic illness DONOR : Concurrent treatment strong inhibitor hepatic cytochrome P450 ( CYP ) 3A4 ( i.e . clarithromycin , erythromycin , protease inhibitor , azole antifungal ) DONOR : Current use statin drug DONOR : Failure meet Fred Hutchinson Cancer Research Center ( FHCRC ) local criterion stem cell donation DONOR : Total creatinine kinase &gt; 2 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>